Aprea reports second partial response for APR-1051; endometrial cancer with PPP2R1A mutation

Aprea Therapeutics, Inc.

Second unconfirmed partial response (uPR) at 220 mg dose: 50% tumor shrinkage (RECIST v1.1) and CA-125 drop from 362 to 47 U/mL (-87%).
Both uPRs observed in endometrial cancer patients with PPP2R1A mutations; both remain on therapy with only Grade 1 adverse events.
Total 22 patients dosed (10–220 mg); five stable disease across four tumor types including HPV-positive HNSCC and FBXW7-mutated colon cancer.
First uPR previously reported at 150 mg; data support genomically guided WEE1 inhibition with favorable tolerability to date.
Next data update expected Q2 2026; enrollment continues at 220 mg and expansion in PPP2R1A endometrial and HPV-positive HNSCC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.